GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » EV-to-EBITDA

CRVS (Corvus Pharmaceuticals) EV-to-EBITDA : -9.39 (As of Jul. 16, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Corvus Pharmaceuticals's enterprise value is $292.39 Mil. Corvus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-31.13 Mil. Therefore, Corvus Pharmaceuticals's EV-to-EBITDA for today is -9.39.

The historical rank and industry rank for Corvus Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

CRVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.52   Med: 0   Max: 0
Current: -9.39

CRVS's EV-to-EBITDA is ranked worse than
100% of 461 companies
in the Biotechnology industry
Industry Median: 10.21 vs CRVS: -9.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-16), Corvus Pharmaceuticals's stock price is $4.17. Corvus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.980. Therefore, Corvus Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Corvus Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Corvus Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals EV-to-EBITDA Chart

Corvus Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.37 -1.22 - -2.60 -11.38

Corvus Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 -2.89 -11.56 -11.38 -5.58

Competitive Comparison of Corvus Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Corvus Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corvus Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's EV-to-EBITDA falls into.


;
;

Corvus Pharmaceuticals EV-to-EBITDA Calculation

Corvus Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=292.390/-31.133
=-9.39

Corvus Pharmaceuticals's current Enterprise Value is $292.39 Mil.
Corvus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corvus Pharmaceuticals  (NAS:CRVS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Corvus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.17/-0.980
=At Loss

Corvus Pharmaceuticals's share price for today is $4.17.
Corvus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.980.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Corvus Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Corvus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Executives
William Benton Jones officer: See Remarks 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Miller Richard A Md director, officer: President and CEO PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
Leiv Lea officer: Chief Financial Officer PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell director 1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher officer: Chief Medical Officer 863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould director, 10 percent owner C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy officer: EVP Discovery Research CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt officer: SVP, Chief Business Officer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner officer: V.P., Chemistry Research 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010